• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Agomelatine (L(+)-Tartaric acid) Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5752671

Agomelatine (S-20098) L(+)-Tartaric acid is a specific agonist of MT1 and MT2 receptors (Kis: 0.1, 0.06, 0.12, and 0.27nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2). It also is a selective 5-HT2C receptor antagonist (pKis: 6.4 and 6.2 at native (porcine)… More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Agomelatine (L(+)-Tartaric acid), Inhibitor
Full Product Name
Agomelatine (L(+)-Tartaric acid)
Product Synonym Names
S-20098 L(+)-Tartaric acid
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
393.39
Solubility
<1mg/ml refers to the product slightly soluble or insoluble
Formula
C19H23NO8
SMILES
CC(NCCC1=C2C=C(OC)C=CC2=CC=C1)=O.O=C(O)[C@H](O)[C@@H](O)C(O)=O
CAS Number
824393-18-2
Target & IC50
CHO-hMT1: ic50 0.1nM (ki)
HEK-hMT1: ic50 0.06nM (ki)
CHO-hMT2: ic50 0.12nM (ki)
HEK-hMT2: ic50 0.27nM (ki)
native porcine 5-HT2C receptor: ic50 6.4 (pki)
human 5-HT2C receptor: ic50 6.2 (pki)
In Vitro
Agomelatine (25, 50, or 75mg/kg; i.p.) has antioxidant activity in Strychnine (75mg/kg, i.p.) or Pilocarpine (400mg/kg, i.p.) induced seizure models in mice. Agomelatine does not have any antioxidant effects on parameters of oxidative stress produced by Pentylenetetrazole (PTZ) or Picrotoxin (PTX) induced seizure models when compared to controls [3].

Product References and Citations for Agomelatine (L(+)-Tartaric acid), inhibitor

Audinot V, et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61.
Audinot V, et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61.
Millan MJ, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003 Sep;306(3):954-64.
Millan MJ, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003 Sep;306(3):954-64.
Aguiar CC, et al. Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures. Cell Mol Neurobiol. 2013 Aug;33(6):825-35.
Aguiar CC, et al. Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures. Cell Mol Neurobiol. 2013 Aug;33(6):825-35.

Other Notes

Small volumes of Agomelatine (L(+)-Tartaric acid), inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Agomelatine (L(+)-Tartaric acid) purchase

MBS5752671 is an inhibitor targeting Agomelatine (L(+)-Tartaric acid).
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000